Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Mills

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
Antiviral Therapy|November 3, 2010
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trialsChristine Katlama, Bonaventura Clotet, Anthony Mills, et al.
AIDS Research and Therapy|October 27, 2024
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United StatesGerald Pierone, Jennifer S Fusco, Laurence Brunet, et al.
Lancet (London, England)|July 19, 2011
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialJean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
The Lancet. Infectious Diseases|June 9, 2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trialAnton Pozniak, Martin Markowitz, Anthony Mills, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot studyAnthony Mills, Donna Mildvan, Daniel Podzamczer, et al.
The Journal of Antimicrobial Chemotherapy|December 25, 2019
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adultsScott L Letendre, Anthony Mills, Debbie Hagins, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
Antiviral Therapy|November 3, 2010
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trialsChristine Katlama, Bonaventura Clotet, Anthony Mills, et al.
AIDS Research and Therapy|October 27, 2024
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United StatesGerald Pierone, Jennifer S Fusco, Laurence Brunet, et al.
Lancet (London, England)|July 19, 2011
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialJean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, et al.
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
The Lancet. Infectious Diseases|June 9, 2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trialAnton Pozniak, Martin Markowitz, Anthony Mills, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot studyAnthony Mills, Donna Mildvan, Daniel Podzamczer, et al.
The Journal of Antimicrobial Chemotherapy|December 25, 2019
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adultsScott L Letendre, Anthony Mills, Debbie Hagins, et al.
Pageof 6